Final answer:
Roflumilast (Daliresp) is used to reduce the risk of exacerbations in patients with severe or very severe COPD and is not a bronchodilator nor does it provide relief of acute bronchospasm. It is suitable for combination use with a LABA and other COPD maintenance therapies.
Step-by-step explanation:
Roflumilast (Daliresp) in COPD Treatment
Roflumilast (Daliresp) is a medication prescribed for patients with COPD (Chronic Obstructive Pulmonary Disease) to reduce the risk of exacerbations in those who have a severe or very severe form of the disease. Unlike bronchodilators that act to quickly open up the airways, roflumilast is a phosphodiesterase-4 inhibitor, which works by reducing inflammation in the lungs and has a more long-term effect on disease progression. This medication does not provide immediate relief of acute bronchospasm, and it is also not intended to be a bronchodilator.
Roflumilast is recommended for patients who have experienced frequent exacerbations despite using other COPD medications. It should be noted that roflumilast can be used in combination with a LABA (long-acting beta agonist) or other maintenance therapies for COPD, as there are no contraindications indicating it should not be used with these medications. When managing COPD, avoiding triggers and the use of appropriate medications, including corticosteroids for long-term control, are key strategies in addition to roflumilast for those who are prone to exacerbations.